Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
Publication Date
9-1-2022
Volume
28
Issue
10
First Page
1576
Last Page
1590
Document Type
Open Access Publication
DOI
10.1177/13524585221079731
Rights and Permissions
Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, Giacomini PS, Saccà F, Mancione L, Zielman R, Bagger M, Das Gupta A, Häring DA, Jehl V, Kieseier BC, Pingili R, Stoneman D, Su W, Willi R, Kappos L. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Mult Scler. 2022 Sep;28(10):1576-1590. doi: 10.1177/13524585221079731. © The Author(s), 2022. CC-BY-NC
Recommended Citation
Hauser, Stephen L; Cross, Anne H; Winthrop, Kevin; Wiendl, Heinz; Nicholas, Jacqueline; Meuth, Sven G; Giacomini, Paul S; Saccà, Francesco; Mancione, Linda; Zielman, Ronald; Bagger, Morten; Das Gupta, Ayan; Häring, Dieter A; Jehl, Valentine; Kieseier, Bernd C; Pingili, Ratnakar; Stoneman, Dee; Su, Wendy; Willi, Roman; and Kappos, Ludwig, "Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years." Multiple sclerosis (Houndmills, Basingstoke, England). 28, 10. 1576 - 1590. (2022).
https://digitalcommons.wustl.edu/oa_4/14
figure 1.docx (66 kB)
figure 2.docx (103 kB)
figure 3.docx (84 kB)
table 1.docx (19 kB)
table 2.docx (15 kB)
tabl 3.docx (15 kB)
table 4.docx (13 kB)
table 5.docx (15 kB)
infographic.pdf (2022 kB)
